At the beginning of the new year, Trinomab announced the appointment of Dr. Li Guo as Vice President of the company, who is responsible for pre-clinical and BA team management to further standardize and strengthen research and development of innovative antibody drugs .

Dr. Li is a senior researcher in the biomedical industry and a toxicologist certified by the Chinese Society of Toxicology. Dr. Li has published 14 papers in peer-reviewed journals. Dr. Li has accumulated more than 13 years of experience in preclinical drug development. He had worked in Hong Kong New Alpha Innovation, Zhuhai Livzon MAB and Guangzhou LintonPharm, and completed the non-clinical efficacy, pharmacokinetics and safety evaluation of a number of macromolecular drugs including monoclonal antibodies, ADC and recombinant proteins etc. Dr. Li  had experience in successful completion of the development, validation and sample bioanalytical analysis of samples of clinical trials for multiple macromolecular drugs.

Prior to joining Trinomab, Dr. Li was the Senior Director of Bioanalysis at WuXi AppTec Shanghai, leading a team of bioanalytical scientists to provide GLP compliant clinical bioanalytical services to world-class biopharmaceutical companies. During his tenure as Director of Preclinical Development at CK Life Sciences in Hong Kong, he led the team in drug discovery for cancer immunotherapy and developed a number of therapeutic cancer vaccines.

Dr. HUAXIN LIAO, Chairman and CTO of Trinomab, said:

The highly efficient HitmAb® platform of Trinomab has effectively promoted the development of multiple innovative antibody drugs in company’s R & D pipeline. In addition to two products in clinical trials, trinomab will have several more of  innovative drugs to open the IND application and enter the clinical trials in near future. We are very pleased to announce the appointment of Dr. Li Guo  to lead the pre-clinical and BA team of professionals at this critical stage of development of the company. With more than 13 years of preclinical drug research and development and nearly 10 years of bioanalytical experience in the field of innovative drugs, Dr. Li will further enhance the successful development of of the company's innovative pipeline.

Dr. Li said:

Trinomab is an international company with great potential for the research and development and industrialization of fully human antibody new drugs. I look forward to working with Trinomab team to continue improving the pre-clinical development and BA work of the company's products. Relying on the company's original fourth-generation antibody technology, original innovation and differentiated layout in the field of global drug development in anti-infection, I believe that Trinomab will continue to move forward with the vision of “Trinomab therapeutics for you regardless poor or rich, in sickness or health”, and transform scientific research breakthroughs into innovative drugs that patients are eager to look forward to.

About Trinomab

Trinomab Biotech Co., Ltd. is a clinical stage biopharmaceutical company with a global expansion perspective. The company is mainly engaged in R&D of novel fully native human mAb drugs. The core technology of the company is known as the fourth-generation antibody technology HitmAb^®, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs as therapeutics against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.

Upholding the mission of “create clinical value”, TNM001 injection (anti-RSV long-acting monoclonal antibody) and TNM002 injection (anti-tetanus toxin monoclonal antibody), the core products of Trinomab have entered the clinical stage one after another. At present, TNM001 is in clinical phase Ib/IIa; TNM002 has officially entered phase III clinical trials, and has obtained the Breakthrough Therapy of CDE in China and the Fast Track Designation of FDA in the United States. In addition, a number of products are in the IND stage, with multiple early development projects are under continuous research and development.